Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People of any gender, aged 18 or older
- People who are able to give written consent to take part in the trial
- People diagnosed with triple-negative breast cancer (TNBC), meaning the cancer cells tested negative for hormone receptors (ER/PR at 0–9%) and negative for HER2, confirmed on both the initial biopsy and the tissue removed during surgery
- People with stage I TNBC where the invasive tumour measured no more than 2 cm, and where the cancer had not spread to any lymph nodes (certain very small or borderline findings may not qualify — confirm with trial site)
- People whose imaging scans (including a specific full-body scan called an 18F-FDG-PET/CT, or a CT scan if that is not available) showed no signs of cancer spread to lymph nodes or other parts of the body
- People whose cancer tissue showed a high level of immune cells (called tumour-infiltrating lymphocytes, or TILs) in the surgical sample — at least 50% for people aged 40 or older at diagnosis, and at least 75% for people under 40 at diagnosis, confirmed by both local and central review
- People who have already had surgery to remove the breast cancer (either breast-conserving surgery or mastectomy), including a procedure to check the lymph nodes
- People who show no signs of the cancer coming back between surgery and expressing their preference about taking part
- People for whom radiotherapy is considered appropriate, if it has been recommended
Who may not be able to join:
- People with a previous history of invasive or non-invasive breast cancer, or who are currently being treated for breast cancer
- People whose breast cancer is found in multiple areas of one or both breasts at the time of screening
- People who received systemic treatment (such as chemotherapy) before their breast surgery
- People whose biopsy or surgical tissue showed signs that cancer cells had spread into blood vessels or lymph vessels (lymphovascular invasion)
- People who have had another invasive cancer within the past 5 years — although certain exceptions may apply, such as some types of skin cancer, localised cervical cancer, or low-grade localised prostate cancer (confirm with trial site)
- People with a serious illness or medical condition that is not well controlled
- People whose personal, psychological, family, or geographic circumstances may make it difficult to follow the trial's schedule and requirements (the trial site will discuss this with the person before enrolment)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Marleen Kok, MD, Antoni van Leeuwenhoek
Phone: +31205129111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Disease recurrence Free Interval (DRFI) - optimalisation cohort per-protocol population
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.